Xeris Biopharma Holdings Stock Price, News & Analysis

Xeris Biopharma Holdings (Nasdaq: XERS) has announced it will release its fourth quarter and full-year 2024 financial results before U.S. markets open on March 6, 2025. The company will also provide 2025 financial guidance during this release.

Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. The company currently has three commercially available products: Recorlev® for endogenous Cushing's syndrome, Gvoke® for severe hypoglycemia treatment, and Keveyis® for primary periodic paralysis. Their pipeline includes XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, along with early-stage programs utilizing their XeriSol® and XeriJect® technology platforms.

Xeris Biopharma Holdings (Nasdaq: XERS) has appointed Dr. Anh Nguyen as Chief Medical Officer (CMO), succeeding Ken Johnson, who will retire on April 1, 2025. Dr. Nguyen, who previously worked at Xeris, will oversee the company's Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions.

Dr. Nguyen brings significant experience in developing first-in-class therapies and has previously served as Vice President at Asklepios Biopharmaceutical. His past achievements include contributing to the '21st Century Cures Act' and leading Gvoke®'s NDA and MAA approvals during his previous tenure at Xeris. The transition comes as Xeris prepares for Phase 3 development of XP-8121 and continues to grow its commercial portfolio, particularly Recorlev®.

Xeris Biopharma Holdings (Nasdaq: XERS) has announced its participation in three major upcoming healthcare investor conferences in early 2025. The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, featuring a fireside chat at 1:20 pm ET. Subsequently, Xeris will attend the Leerink Global Healthcare Conference in Miami on March 10, with a fireside chat scheduled for 8:40 am ET, followed by the Barclays 27th Annual Global Healthcare Conference in Miami on March 11 for 1x1 meetings only.

The growth-oriented biopharmaceutical company, focused on developing and commercializing innovative therapeutic products, will have its senior management team available for one-on-one meetings at all three events. Interested parties can access webcast information for the fireside chats through Xeris' investor relations website.

The American Diabetes Association (ADA) and Xeris Pharmaceuticals have announced a multi-year strategic partnership to promote awareness about glucagon prescriptions for diabetes patients. The collaboration focuses on emphasizing that all individuals with diabetes on blood glucose-lowering medications should have glucagon, preferably in ready-to-use form.

Key statistics highlight that up to 46% of type 1 diabetes patients and 21% of type 2 diabetes patients using insulin experience at least one severe hypoglycemia event annually. These events result in over 202,000 emergency department visits yearly, with 25% requiring hospitalization.

The partnership aims to develop educational materials and training resources for healthcare professionals and diabetes patients, alongside launching a national awareness campaign. The initiative aligns with ADA's updated Standards of Care in Diabetes—2025, addressing the critical need for proper glucagon prescription rates and emergency preparedness for those at risk of severe hypoglycemia.

Xeris Biopharma Holdings (XERS) has announced it expects to exceed its 2024 financial guidance with projected total revenue of $203 million, surpassing previous guidance of $198-$202 million. The company anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, achieving positive cash flow in Q4.

Q4 2024 highlights include $60 million in total revenue, representing 35% growth, with Recorlev® net revenue increasing approximately $5 million (28%) sequentially. Gvoke® achieved approximately 35% market share, while Keveyis® maintained stable patient numbers. The company received a $3 million milestone payment from Beta Bionics for developing a XeriSol® glucagon formulation. However, Amgen terminated its exclusive worldwide license agreement following a portfolio assessment.

Xeris Biopharma Holdings (XERS) has announced the granting of restricted stock units (RSUs) to 19 new employees as part of its Inducement Equity Plan. The Compensation Committee of Xeris' Board of Directors approved the grants on January 2, 2025, consisting of an aggregate of 181,500 shares of common stock.

The RSUs will vest over a three-year period in equal annual installments, contingent upon the employees' continued employment with Xeris or its subsidiaries. These equity awards were granted exclusively to new hires as an employment inducement under NASDAQ Listing Rule 5635(c)(4).

Xeris Biopharma Holdings (Nasdaq: XERS) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management will engage in a fireside chat scheduled for December 3, 2024, at 8:00am Eastern Time. The event will be accessible through a live webcast on the 'Events & Presentations' section of Xeris' Investor Relations website, with a replay available for 30 days following the presentation.

Xeris Biopharma reported record Q3 2024 total revenue of $54.3M, with product revenue reaching $52.9M, marking a 27% increase year-over-year and 14% quarter-over-quarter growth. Gvoke revenue grew 29% to $22.9M, while Recorlev revenue surged 119% to $17.7M. However, Keveyis revenue declined 23% to $12.2M. The company raised its full-year revenue guidance to $198M-$202M and ended Q3 with $69.4M in cash. Net loss for Q3 was $15.7M or ($0.11) per share.

Xeris Biopharma Holdings (Nasdaq: XERS) has scheduled the release of its third quarter 2024 financial results before U.S. market opening on November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. ET. The company, focused on developing innovative therapies, currently markets three products: Gvoke® for severe hypoglycemia, Keveyis® for primary periodic paralysis, and Recorlev® for endogenous Cushing's syndrome.